Brokerages Set GeneDx Holdings Corp. (NASDAQ:WGS) PT at $150.71

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $150.7143.

A number of brokerages have recently issued reports on WGS. Piper Sandler reissued an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Canaccord Genuity Group lifted their price objective on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a report on Monday, February 23rd. BTIG Research decreased their target price on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research report on Tuesday, February 24th. Finally, Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 25th.

Insider Buying and Selling

In related news, Director Keith A. Meister acquired 140,026 shares of the stock in a transaction on Thursday, March 5th. The shares were purchased at an average price of $81.19 per share, for a total transaction of $11,368,710.94. Following the purchase, the director directly owned 3,228,150 shares in the company, valued at approximately $262,093,498.50. The trade was a 4.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kevin Feeley sold 6,187 shares of GeneDx stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $78.61, for a total value of $486,360.07. Following the completion of the transaction, the chief financial officer directly owned 18,674 shares of the company’s stock, valued at $1,467,963.14. This represents a 24.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 62,607 shares of company stock worth $6,421,523. 29.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On GeneDx

Several institutional investors and hedge funds have recently bought and sold shares of WGS. Kestra Advisory Services LLC bought a new position in GeneDx in the 4th quarter valued at about $27,000. Jones Financial Companies Lllp lifted its holdings in shares of GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the period. Ramirez Asset Management Inc. bought a new stake in shares of GeneDx during the 4th quarter worth approximately $33,000. Greenline Wealth Management LLC acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $35,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Stock Performance

NASDAQ:WGS traded up $6.11 during mid-day trading on Friday, hitting $88.11. 1,201,655 shares of the stock were exchanged, compared to its average volume of 769,606. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -117.48 and a beta of 2.03. The firm’s 50-day simple moving average is $100.80 and its 200 day simple moving average is $122.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. GeneDx has a fifty-two week low of $55.17 and a fifty-two week high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. As a group, equities analysts anticipate that GeneDx will post 0.97 EPS for the current fiscal year.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.